Would you consider using ensartinib in patients with ALK-positive NSCLC who have progressed on alectinib and lorlatinib?  

I've written about this previously (https://www.themednet.org/question/23471). The question invokes a conceptual model of cancer therapy sequencing from the chemotherapy era, where it was the norm to go through lines of therapy with diminishing returns (e.g., platinum doublet, then docetaxel, then ...